title: Calcium acetate control of serum phosphorus in hemodialysis patients.
abstract: Calcium acetate has many characteristics of an ideal phosphorus binder. It is a readily soluble salt that avidly binds phosphorus in vitro at pH 5 and above. One-dose/one-meal balance studies show it to be more potent than calcium carbonate or calcium citrate. We studied chronic (3-month) phosphorus binding with calcium acetate in 91 hyperphosphatemic dialysis patients at four different centers. All phosphorus binders were stopped for 2 weeks. Calcium acetate at an initial dose of 8.11 mmol (325 mg Ca2+) per meal was then used as the only phosphorus binder. Dose was adjusted to attempt control of predialysis phosphorus level less than 1.78 mmol/L (5.5 mg/100 mL). Final calcium acetate dose was 14.6 mmol (586 mg) Ca2+ per meal. Sixteen patients developed mild transient hypercalcemia (mean, 2.84 mmol/L [11.4 mg/dL]. Initial phosphorus values in mmol/L (mg/dL) were 2.39 (7.4); at 1 month, 1.91 (5.9); and at 3 months, 1.68 (5.2). Initial calcium values in mmol/L (mg/dL) were 2.22 (8.9); at 1 month, 2.37 (9.5); and at 3 months, 2.42 (9.7). Initial aluminum values in mumol/L (micrograms/L) were 2.99 (80.7); and at 3 months were 2.54 (68.4). Initial C-terminal parathyroid hormone (C-PTH) values in ng/mL were 14.6; at 1 month, 11.9; and at 3 months, 13.2. Sixty-nine patients then entered a double-blind study. Phosphorus binders were stopped for 1 week. Calcium acetate (at a dose established in a prior study) or placebo was then administered for 2 weeks. Next, patients were crossed to the opposite regimen for 2 weeks. Initial phosphorus was 2.36 mmol/L (7.3 mg/100 mL) and calcium 2.22 mmol/L (8.9 mg/100 mL).(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Nephrology/Metabolism Division, Baylor University Medical Center, Dallas, TX 75246.
authors.forename: M
authors.initials: M
authors.lastname: Emmett
authors.forename: M D
authors.initials: MD
authors.lastname: Sirmon
authors.forename: W G
authors.initials: WG
authors.lastname: Kirkpatrick
authors.forename: C R
authors.initials: CR
authors.lastname: Nolan
authors.forename: G W
authors.initials: GW
authors.lastname: Schmitt
authors.forename: M B
authors.initials: MB
authors.lastname: Cleveland
mesh_terms: D000085:Acetates / Q000009:adverse effects / Q000627:therapeutic use*; D019342:Acetic Acid; D000328:Adult; D000368:Aged; D000535:Aluminum / Q000097:blood; D002118:Calcium / Q000097:blood; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood / Q000628:therapy; D008297:Male; D008875:Middle Aged; D010281:Parathyroid Hormone / Q000097:blood; D010758:Phosphorus / Q000097:blood*; D006435:Renal Dialysis
chemical_list: D000085:Acetates; D010281:Parathyroid Hormone; D010758:Phosphorus; D000535:Aluminum; D019342:Acetic Acid; D002118:Calcium